Immusoft Corporation

When it comes to engineered cell therapies, the ones currently on the market come from T-cells and have approval for treating some form of cancer, falling into one of three modalities: chimeric antige

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Huadong Pays $20m Up Front For ADCs Fro

Roche Holding AG , Genentech, Inc. and their affiliated companies were the busiest deal makers in the biopharmaceutical sector for the second consecutive year in 2021, with 23 deals across all cate

[Sidebar#SC145549] Biopharmaceutical companies and other life science start-ups may access $1.28bn in new venture capital available through four different sources, including Eir Venture Partners AB’s